Freya Pharma Solutions, a Netherlands-based late clinical stage company, announced on Wednesday that it has named Christa van Kan, MSc as its new director Clinical Operations, effective March 2023.
In this new role van Kan will be responsible for driving the confirmatory clinical development investigating Lybrido, an 'on demand' therapy for the treatment of premenopausal women suffering from Female Sexual Interest/Arousal Disorder (FSIAD).
van Kan has over 25 years of clinical operations and trial management experience. She has served as interim director Clinical Operations at Healx. She co-founded and held the position of director Clinical Operations of PSR Group.
van Kan has an MSc degree in Biomedical Sciences from the State University Leiden in The Netherlands.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer